SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's after-hours surge is fueled by better-than-expected earnings and strong Q4 guidance, particularly driven by AWS growth. Community discussions revolve around potential ATH and target prices, with many regretting not buying more, while some caution against greed and anticipate a pullback. The earnings beat, especially in cloud services, has reignited bullish sentiment around the stock.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's earnings are driving significant discussion, with debates focusing on whether the results justify the company's high valuation and PE ratio. Community members are closely watching guidance for the next quarter, particularly regarding iPhone sales and growth in China. Some traders express concerns about overvaluation and are considering short positions, while others remain bullish, anticipating a continued climb towards higher price targets.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy ($MSTR) is trending following its Q3 earnings report, with community chatter focused on the company's significant earnings beat driven by its Bitcoin holdings. Despite the positive results, some investors express concern over the stock's price movement and the broader context of its business model, while others point to potential S&P 500 inclusion and analyst upgrades as bullish signals.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's stock is trending following a strong earnings report, with revenue and EPS exceeding analyst expectations and user growth remaining solid. The community is buzzing about the potential for a continued rally towards previous highs, although some traders are wary of a possible pullback. Discussions also include the impact of AI and data licensing deals on Reddit's revenue streams, as well as a debate on the stock's valuation relative to its growth.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

RKT is trending as investors discuss the potential for a short squeeze following strong earnings and positive Q4 revenue guidance. Community members are highlighting the high short interest and upcoming catalysts like potential rate cuts and the integration of recent acquisitions. Some are closely watching for analyst upgrades and increased price projections amidst discussions of long-term growth potential in the housing market.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

LUMN is trending due to positive sentiment surrounding its AI connectivity fabric and recent partnerships, particularly with Palantir, fueling speculation about future government contracts. Community members are actively discussing the potential for a significant earnings beat and a re-rating as a tech company, while also weighing the company's debt against its growth prospects in the AI infrastructure space.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending following an analyst upgrade from JP Morgan, with the community noting its outperformance relative to Bitcoin YTD. Bullish sentiment is building ahead of earnings, as investors anticipate a potential breakout driven by increased crypto activity and key partnerships. Some traders are closely watching technical levels, while others express caution based on past earnings reactions.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending following a commercial momentum update for IBSRELA/XPHOZAH and discussion of upcoming pediatric/expansion catalysts. Community members are discussing the company's undervaluation, comparing its financials to similar companies, and highlighting management's confidence. Bullish sentiment is fueled by positive earnings reports and anticipation of upgrades, with some focusing on the potential of their pipeline program.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom ($DXCM) is trending amid concerns over the G7 product's quality and reliability, with some users reporting failures and inaccuracies, while others defend its performance and praise its features; this debate is amplified by a recent short report alleging safety issues with the device. Community discussions also revolve around the potential impacts of a CEO transition, manufacturing locations, and competition from Abbott on Dexcom's future growth and market position. Despite mixed sentiment, some investors express optimism, citing potential for a rebound and upcoming catalysts like new product releases.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

GSAT is trending amid speculation of a potential sale, with SpaceX named as a possible suitor, sparking community discussion around potential buyout prices and the involvement of key partners like Apple. Investors are also weighing the significance of Globalstar's n53 spectrum and potential deals with Amazon and Walmart. Some traders are expressing hope for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Bitcoin (BTC) dropped below $114,000 in&nbsp;pre-market U.S. hours on Wednesday, while Ripple’s native token (XRP), Solana (SOL), Cardano (ADA), and Dogecoin (DOGE) led the slide among&nbsp;other major tokens.The overall cryptocurrency market slipped around 1.3% over the past day, with the overall&nbsp;market capitalization slipping below $3.8 trillion.&nbsp;<a href="http://stocktwits.com/symbol/BTC.X">Bitcoin’s price</a> fell 0.7% in the last 24 hours, while retail sentiment on Stocktwits moved lower in&nbsp;the ‘bearish’ territory. Bitcoin’s current price is 7.2% below its all-time high of over $122,000, seen last month.&nbsp;<a href="http://stocktwits.com/symbol/XRP.X">XRP’s price</a> was down 4.4% and&nbsp;<a href="http://stocktwits.com/symbol/ADA.x">Cardano’s price</a> slipped around 3.9% in pre-market U.S. hours.<a href="https://stocktwits.com/symbol/ETH.X">Ethereum price</a> fell 1.7% in the last 24 hours, still above $3,600. On Stocktwits, retail sentiment around Ethereum remained in ‘bearish’ territory over the past day.&nbsp;<a href="https://stocktwits.com/symbol/SOL.X">Solana’s price</a> fell 4.2% and&nbsp;<a href="https://stocktwits.com/symbol/DOGE.X">Dogecoin’s price</a> dipped 3.6% over the past day.&nbsp;Weakness in the cryptocurrency market&nbsp;persisted as investors continued to withdraw money from U.S.-listed spot Bitcoin exchange-traded funds (ETFs). According to&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://sosovalue.com/assets/etf/us-btc-spot">data</a> from SoSoValue, the daily total net outflow amounted to $196.18 million on Tuesday, with Fidelity’s FBTC (FBTC) and BlackRock’s IBIT (IBIT) accounting for the biggest shares.&nbsp;This is the fourth day of outflows from U.S.-listed spot BTC ETFs, the longest streak since April. More than $114 million was withdrawn on Thursday, followed by $812 million on Friday and $333 million on Monday.Amid a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://blog.coinshares.com/volume-245-digital-asset-fund-flows-weekly-report-e4ac31e2961a">choppy week</a> of ETF flows, $298 million worth of crypto was liquidated over the past day, according to Coinglass&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.coinglass.com/LiquidationData">data</a>. Long liquidations were around $210 million, while short liquidations totaled $87 million. Ethereum experienced the largest liquidations of $89 million, followed by Bitcoin at $43 million.Crypto-linked stocks were in the doldrums during pre-market trade on Wednesday. Shares of Strategy (MSTR), the largest corporate holder of Bitcoin, edged 0.7% higher. Bitcoin miner Riot Platforms (RIOT) stock edged 0.09% higher, and shares of its peer, Mara Holdings (MARA), gained 0.06%. Crypto exchange Coinbase Global’s (COIN) shares were up 1.2% in pre-market trade.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ray-dalio-warns-of-fiat-trust-breakdown-says-gold-standard-return-is-possible/chrLMkxRd20">Ray Dalio Warns Of Fiat Trust Breakdown, Says Gold Standard Return Is Possible</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A neon sign advertises a Bitcoin and Ethereum crypto currency exchange in Warsaw, Poland, on January 4, 2025.

Bitcoin Drops Below $114K With XRP, Solana, Dogecoin Leading The Slide – ETF Outflows Hit $1.3B Over the Last 4 Days

Weakness in the cryptocurrency market remained as investors continued to withdraw money from U.S.-listed spot Bitcoin exchange-traded funds.

Cryptocurrency

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Nasdaq-listed American Depository Receipts (ADRs) of Genmab A/S (GMAB) rose over 1% on Thursday morning after Johnson &amp; Johnson (JNJ)<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/04/15/3061529/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-First-Quarter-of-2025.html"> announced</a> that sales of the oncology drug Darzalex rose over 20% in the first quarter of 2025.Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&amp;J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab.Genmab licensed daratumumab to Johnson &amp; Johnson unit Janssen Biotech, Inc. in August 2012.Darzalex is a prescription medication used to treat multiple myeloma, a type of blood cancer. For the three months through the end of March, Johnson &amp; Johnson reported sales of $3.24 billion for Darzalex, marking a growth of 20.3% year-on-year.Darzalex accounted for over 23% of the company’s overall sales in its innovative medicine segment and nearly 15% of its overall reported sales.Darzalex sales in the U.S. jumped 25% to $1.83 billion during the quarter, while sales outside the country jumped 15% to $1.41 billion.The rise in Darzalex sales enabled the company to offset the 34% drop in sales of its immunology drug Stelara to $1.63 billion.On Stocktwits, retail sentiment around Genmab fell marginally while staying within ‘extremely bullish’ territory over the past 24 hours, while message volume dropped to ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:645/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_9_35_32_AM_png_f443284110.webp" alt="GMAB's Sentiment Meter and Message Volume as of 9:35 a.m. ET on April 14, 2025 | Source: Stocktwits" width="645" height="149"><figcaption>GMAB's Sentiment Meter and Message Volume as of 9:35 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that Genmab shares are cheap.<a href="https://stocktwits.com/Pika_Capital/message/611668890">https://stocktwits.com/Pika_Capital/message/611668890</a><a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> fell by about 7% year-to-date and over 33% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dow-jones-futures-tick-higher-as-investors-await-earnings-monitor-tariff-developments/chQRaHyRbau">Dow Jones Futures Tick Higher As Investors Await Earnings, Monitor Tariff Developments</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab. 

Equity

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a settlement payment with the National Institutes of Health, drawing a cautious response from retail investors.The payment reportedly comprises $750 million as a settlement for claimed royalties during calendar years 2020-2023, and $41.5 million consideration for the NIH towards an amended and restated license agreement, dated December 20.BioNTech, a clinical-stage biotechnology company, focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases.BioNTech had been in discussions with the National Institutes of Health concerning royalties and other amounts allegedly owed on certain sales along with its collaboration partner Pfizer in connection to COVID-19 vaccine, the Fly.com reported.Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.<stembedurl>https://stocktwits.com/taxplanr/message/597983247</stembedurl> <stembedurl>https://stocktwits.com/taxplanr/message/597861544</stembedurl> &nbsp;The Fly.com report said the company's execution of the settlement agreement wasn’t an admission of liability as the company denied it had any legal liabilities or was in violation of any laws.NIH has reportedly agreed to consider any alleged noncompliance under the amended license agreement to be resolved for the period up to and including January 1, 2024, including any claimed historical royalty payments allegedly owed by the company prior to January 1, 2024.In parallel, BioNTech and the NIH also entered into the amended license agreement that provides a “framework” for a license for use in combination products including the COVID-19 vaccine used in combination with other active pharmaceutical ingredients.The settlement agreement requires Pfizer to reimburse BioNTech for $364.5 million of the claimed royalties paid to the NIH for 2020-2023 sales, the report added.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious

Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.

BeiGene (<a class="mention" data-mention="$BGNE" data-symbol-id="BGNE" href="https://stocktwits.com/symbol/BGNE" target="_blank">$BGNE</a>) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high after the European Commission approved its drug Tevimbra (Tislelizumab) for first-line treatment of gastric and esophageal cancers.The approval allows Tevimbra, in combination with chemotherapy, to treat esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction adenocarcinoma.&nbsp;Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone, demonstrating statistically significant and clinically meaningful benefits.Mark Lanasa, Chief Medical Officer for Solid Tumors at BeiGene, emphasized Tevimbra’s role as the cornerstone of the company’s solid tumor portfolio, noting that more than 1.3 million patients worldwide have been treated with the drug.&nbsp;The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.Esophageal cancer, which accounts for over 90% of esophageal squamous cell carcinoma cases, is one of the deadliest cancers. Beigene says it is projected to increase by nearly 60% to 957,000 annual cases by 2040, highlighting the urgent need for better treatment options.BeiGene has been expanding rapidly, recently reporting $1 billion in quarterly revenue, driven by U.S. and European product sales, and opening an $800 million R&amp;D and manufacturing facility in New Jersey.&nbsp;The company had also announced plans to rebrand as “BeOne Medicines Ltd.” and change its ticker to “ONC” following shareholder approval, signaling its commitment to global oncology leadership.<figure class="image"><a href="https://stocktwits.com/symbol/BGNE"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BGNE_sentiment_and_message_volume_Nov_27_premarket_749418ab8f.png" alt="BGNE sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>BGNE sentiment and message volume Nov 27 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’ early on Wednesday following the approval news, accompanied by a surge in message volume.&nbsp;TD Cowen recently reiterated a ‘Buy’ rating on BeiGene and raised its price target to $260, citing the company’s robust pipeline, which it described as among the best in biotech.BeiGene stock has gained more than 8% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-slides-after-fuzzy-panda-short-call/cJIWDFNRWc">ASP Isotopes Stock Fizzles After Fuzzy Panda Short Call: Retail Eyes Opportunity</a>

Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone.

BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

FBT
First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Feed

News

Sentiment

Fundamentals

Info

Latest FBT News

FBTFirst Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund